Genomics can help to identify people who are more likely to develop glaucoma potentially long before any symptoms of the disease appear. Instead ...

The introduction of the first disease-modifying therapies fundamentally transformed the management of geographic atrophy and brought new changes and challenges in clinical practice, workflow and ...

OT heard from outgoing chairman, Nick Rumney, and BBR Optometry’s CEO Nick Black and director Suzanne Wadsworth about the ways the practice has evolved and the changes ahead ...

Traditional eye imaging technology powered up by new techniques and AI provides a unique in-depth look at wounds as they heal over time.

No matter the size or severity, wounds on human skin are difficult to monitor while they heal. Biopsies disrupt the wound site and are too invasive for routine, repeated monitoring, and most medical ...

ChemR23 agonism targets inflammatory and neurosensory biology, with receptor expression on ocular immune cells and dorsal root ganglion neurons/glia supporting a mechanistic rationale for NCP symptom ...

Annexon (NASDAQ:ANNX) used its Investor Day presentation to outline the scientific rationale and clinical progress for ...

Prostacyclin analogues for pulmonary arterial hypertension may reduce the risk for developing nonproliferative diabetic retinopathy.

The skeletal effects of GLP-1RAs vary on the basis of diabetes status, with weight loss driving bone loss among patients without diabetes.